

Docket No.: 256653US0PCT

OBLON
SPIVAK
MCCLELLAND
MAIER
A
NEUSTADT
BC.

ATTORNEYS AT LAW

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 10/502,051

Applicants: Takashi KADOWAKI, et al.

Filing Date: July 30, 2004

For: INSULIN RESISTANCE IMPROVING AGENT

Group Art Unit: 1647

Examiner: ROMEO, DAVID S.

SIR:

Attached hereto for filing are the following papers:

RESPONSE TO RESTRICTION REQUIREMENT

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C. Norman F. Oblon

Jay E. Rowe, Jr.

Registration No. 58,948

Customer Number 22850

(703) 413-3000 (phone) (703) 413-2220 (fax)



DOCKET NO: 256653US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

TAKASHI KADOWAKI, ET AL. : EXAMINER: ROMEO, DAVID S.

SERIAL NO: 10/502,051

: GROUP ART UNIT: 1647 FILED: JULY 30, 2004

FOR: INSULIN RESISTANCE

IMPROVING AGENT

RESPONSE TO RESTRICTION REQUIREMENT

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Office Action dated October 13, 2006, Applicants elect, with traverse, Group I, Claims 1 and 3, to the extent that they are drawn to an agent containing adiponectin, for examination.

Remarks/Arguments begin on page 2 of this paper.